Avience Biomedicals Reports FY2026 Results: Revenue Reaches 5,279.50 Lakhs in Consolidated Standalone Statement
Avience Biomedicals Limited has released its audited standalone and consolidated financial results for the year ended March 31, 2026. The company reported significant operational performance alongside key activities, including an Initial Public Offering (IPO) completed subsequent to the financial period.The Company's Board of Directors approved these results during a meeting held on July 16, 2026. Independent auditors issued an Unmodified Audit Opinion regarding the standalone financial statements for the year ended March 31, 2026.
Financial Performance Highlights (Standalone Results)
For the year ending March 31, 2026, Avience Biomedicals recorded a profit of 319.20 Lakhs in the standalone results. The company's operations and financial position are detailed below:| Particulars | Half Year Ended Mar 31, 2026 (Audited) | Half Year Ended Mar 31, 2025 (Audited) | Year Ended Mar 31, 2026 (Audited) | Year Ended Mar 31, 2025 (Audited) |
|---|---|---|---|---|
| Revenue from operations | 1,606.51 | 1,924.96 | 3,531.47 | 2,888.95 |
| Total Revenue | 1,618.93 | 1,930.90 | 3,549.83 | 2,953.76 |
| Total expenses | 1,144.05 | 1,457.55 | 2,101.60 | 2,259.74 |
| Profit before tax | 474.88 | 473.35 | 948.23 | 694.02 |
| Profit for the period/year | 319.20 | 354.13 | 673.33 | 500.21 |
Consolidated Financial Results Report
The consolidated financial results, which include the subsidiary DR Meditech Surgical & Diagnostics (India) Private Limited, show a Total Income of 2,591.63 Lakhs for the half year ended March 31, 2026, and a total income of 5,279.50 Lakhs for the full financial year ending March 31, 2026.| Particulars | Half Year Ended Mar 31, 2026 (Audited) | Half Year Ended Mar 31, 2025 (Audited) | Full Year Ended Mar 31, 2026 (Audited) | Full Year Ended Mar 31, 2025 (Audited) |
|---|---|---|---|---|
| Total Income | 2,591.63 | 2,687.87 | 5,279.50 | 4,590.84 |
| Total Expenses | 1,955.13 | 2,077.79 | 4,032.92 | 3,606.47 |
| Profit before tax | 636.50 | 610.08 | 1,246.58 | 984.38 |
| Profit for the period/year after minority interest | 421.50 | 453.78 | 875.28 | 709.90 |
Balance Sheet and Cash Flow Summary
The consolidated balance sheet as of March 31, 2026, shows total equity and liabilities at 7,794.39 Lakhs. Key components of the balance sheet include:| Particulars | As at Mar 31, 2026 (Rs. Lakhs) | As at Mar 31, 2025 (Rs. Lakhs) |
|---|---|---|
| Share Capital | 403.13 | 403.13 |
| Reserves and Surplus | 2,738.12 | 1,862.85 |
| Long-term Borrowings | 1,322.87 | 984.95 |
| Short-term Borrowings | 1,570.61 | 1,230.87 |
| Total Equity and Liabilities | 7,794.39 | 5,648.84 |
In terms of cash flow from operating activities, the company generated a net cash amount of 590.62 Lakhs for the year ended March 31, 2026, compared to 339.43 Lakhs for the same period in the prior year. Cash and cash equivalents stood at 227.47 Lakhs at the end of March 31, 2026.
Corporate Activities
The Company successfully completed an Initial Public Offering (IPO) subsequent to the financial year ended March 31, 2026. This IPO involved 14,53,800 equity shares with a face value of Rs 10 each and an issue price of Rs 208 per equity share. The shares were listed on SME Portal National Stock Exchange of India Limited (NSE EMERGE) effective June 25, 2026.The net proceeds from the fresh IPO are designated for three primary uses:
- To partially finance capital expenditure for setting up a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh.
- Funding working capital requirements of the Company.
- General corporate purpose.
AVIENCE Stock Price Movement
Shares of Avience Biomedicals are edging higher to the ₹260 mark at 3:27 PM today, buoyed by a gain of ₹0.25 or 0.1%. The stock saw notable trading activity, with 64,800 shares changing hands in the Live Market.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: